Cogent Biosciences enters September with an uncomfortable split: short sellers have been quietly adding positions for weeks while the analyst community sits firmly in the bull camp, leaving the stock caught between accumulating bearish pressure and a consensus price target implying roughly 60% upside from current levels.
The short-side story has been steadily building. At 12.6% of the free float, short interest is genuinely elevated for a small-cap biotech — and it has climbed 9% over the past week and more than 20% over the past month, a meaningful acceleration. The ORTEX short score has drifted up to 60.4, its highest reading in at least two weeks, reflecting the direction of travel. That said, the borrow market tells a far calmer story. Availability is loose at around 708% — roughly seven shares available for every one currently borrowed — and cost to borrow is running near 0.49%, down sharply from above 0.6% six weeks ago. This is not a squeeze setup. Shorts are adding exposure, but they are doing so cheaply and comfortably, which suggests deliberate conviction rather than a crowded, fragile position. The stock itself has shed nearly 11% over the past month to close at $34.68.
Options positioning adds a different wrinkle. Call-side dominance is extreme: the put/call ratio has dropped to just 0.11, close to its 52-week low of 0.11 and nearly 1.4 standard deviations below its 20-day average of 0.19. That reading has held near these levels for the past several sessions, after PCR was running closer to 0.23–0.31 through July and early August. The shift is notable — it suggests that whatever hedging demand existed earlier has evaporated, replaced by a skew toward upside calls. Shorts are building, but the options market is leaning the other way.
Analysts align with the options optimism. The recent moves are worth noting: Piper Sandler lifted its target to $55 on August 17th, and Guggenheim raised to $52 on August 12th, both maintaining positive ratings. The broader panel of active coverage is uniformly constructive, with targets clustering in the $52–$55 range against a current price of $34.68. The bull case centers on bezuclastinib, Cogent's lead KIT inhibitor, with two near-term FDA decisions flagged for 2026 and cash runway extending into late 2028. Bears point to a deeply negative earnings profile — the EV/EBITDA multiple is a loss-making -18.8x — and competition risk from established treatments. The ORTEX short score rank of 21 and days-to-cover rank of 21 reflect a market that considers the short setup moderately elevated relative to peers, while the EPS surprise score of 55 sits near the median, offering no particular edge to either camp from the fundamental delivery angle.
One activist flag deserves attention. Fairmount Funds Management holds a Schedule 13D position — an activist designation — and its stake has been declining, from 9.9% to 8.6% as last disclosed in a March 2026 amendment. Insider activity over the past 90 days has been marginally net negative at roughly -$1.7 million, though the most recent trades in late August from director Arlene Morris were executed under a pre-arranged 10b5-1 plan, reducing the signal value. Stakes from Deerfield and Point72 have also been trimmed according to recent 13G filings. The direction of travel among some specialist healthcare funds is cautious, even as the indexers — FMR at 14.8%, BlackRock at 10% — have been adding. As always, 13D/G disclosures are point-in-time around the 5% threshold; actual current positions may differ.
Earnings are not due until early November, so the near-term catalyst calendar falls squarely on FDA pipeline timelines for bezuclastinib. The tension to watch is whether the building short interest reflects genuine doubt about those outcomes, or whether it represents hedged longs that will unwind sharply on a positive readout — the next regulatory milestone is the variable that resolves the current standoff between a crowded call book and a rising short count.
See the live data behind this article on ORTEX.
Open COGT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
